The new minimally-invasive therapy, called Aquablation, is delivered through the HYDROS Robotic System. This technology is clinically proven to provide significant BPH symptom relief in prostates of all shapes and sizes.
“This new therapy ensures that we are meeting the healthcare needs of families in our region,” said Sean McAfee, Interim President and CEO of St. Vincent’s St. Johns County. “Adding this minimally-invasive procedure will make sure we’re providing the best treatment options available for a condition that affects the majority of men as they age.”
BPH is a non-cancerous enlargement of the prostate gland that affects most men as they age, with 80-90% of men over 70 developing this condition. Common symptoms include urgent or frequent urination, especially at night. Without treatment, BPH can cause permanent bladder or kidney damage, bladder stones or incontinence.
This minimally-invasive technology delivers both safety and efficacy. It uses ultrasound-guided, robotic-assisted waterjet technology that allows surgeons to create a personalized treatment plan that precisely targets problematic tissue while preserving healthy anatomy. This tailored approach removes problematic tissue while protecting critical anatomy.
Clinical data shows Aquablation therapy provides significant symptom relief while preserving function and continence.
